Enanta Pharmaceuticals (ENTA) to Release Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) is scheduled to issue its quarterly earnings data after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $15.17 on Friday. The business’s 50-day simple moving average is $14.92 and its 200 day simple moving average is $11.98. The company has a market cap of $320.94 million, a P/E ratio of -2.31 and a beta of 0.54. Enanta Pharmaceuticals has a one year low of $8.08 and a one year high of $37.14.

Analyst Ratings Changes

ENTA has been the subject of a number of recent analyst reports. StockNews.com lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, April 6th. JPMorgan Chase & Co. lowered their price target on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Thursday, February 8th. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $19.33.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.